Zeposia (ozanimod) — Highmark

Initial criteria

• age ≥ 18 years
• diagnosis of multiple sclerosis classified as one of the following relapsing forms: clinically isolated syndrome, relapsing-remitting disease, active secondary progressive disease

Reauthorization criteria

• member has experienced a therapeutic response defined as disease stability, disease improvement, or delayed disease progression

Approval duration

24 months